|
Related party transactions (Detail Textuals )
|
12 Months Ended | 45 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
USD ($)
|
Dec. 31, 2013
CAD
|
Dec. 31, 2012
USD ($)
|
Dec. 31, 2011
USD ($)
|
Dec. 31, 2013
USD ($)
|
Jan. 25, 2013
Valent Technologies, LLC
|
Dec. 31, 2013
Valent Technologies, LLC
USD ($)
|
Apr. 30, 2012
Valent Technologies, LLC
Accounts Payable
|
Dec. 31, 2013
Officer and Director
USD ($)
|
|
| Related Party Transaction [Line Items] | |||||||||
| Cash compensation to officers | $ 454,549 | ||||||||
| Aggregate amount owing to officers and directors for fees and expenses | 109,030 | 447,777 | 109,030 | ||||||
| Clinical development costs included in accounts payable | 44,007 | ||||||||
| Shares issued for the settlement of accounts payable (in shares) | 500,000 | ||||||||
| Loan payable to Valent | 272,372 | ||||||||
| Interest expense | 8,020 | 7,521 | 21,933 | 37,474 | 22,372 | ||||
| Stock issued in exchange for reduction in royalties | 1,150,000 | 1,150,000 | 1,150,000 | ||||||
| Payments of stock issuance costs | 598,000 | ||||||||
| Stock options granted | 900,000 | 900,000 | 1,410,000 | ||||||
| Exercise price | $ 0.47 | 0.50 | $ 1.05 | ||||||
| Director fees recognized | $ 44,333 | ||||||||